Palghar (Maharashtra)-based CDMO manufacturing nutraceuticals, cosmetics, ayurvedic/herbal formulations, veterinary feed supplements and homecare products for third-party brands.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 0 | 0 | 0 | 0 | 18 | 23 | 23 |
| Reserves | 0 | 4 | 12 | 23 | 18 | 67 | 78 |
| Borrowings | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0 | 12 | 16 | 18 | 34 | 23 | 23 |
| Total Liabilities | 0 | 18 | 28 | 41 | 70 | 114 | 124 |
| AssetsFixed Assets | 0 | 3 | 6 | 14 | 19 | 24 | 28 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 34 | 2 |
| Other Assets | 0 | 15 | 22 | 27 | 52 | 55 | 90 |
| Total Assets | 0 | 18 | 28 | 41 | 70 | 114 | 124 |
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 0 | 4 | 7 | 9 | 7 | 4 |
| Cash from Investing | 0 | -3 | -5 | -8 | -9 | -25 |
| Cash from Financing | 0 | 1 | 0 | -1 | 0 | 45 |
| SummaryCapital Expenditure | — | — | — | — | — | — |
| Free Cash Flow | 0 | 1 | 2 | 1 | -1 | -21 |
| FCF Margin | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (12.5×) and current (14.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 10% growth and a 12× exit, ₹240 only delivers your return if you pay ₹135. The price is currently baking in 22% growth.
EPS grows 10%/yr for 5 years, then fades to 6% over 2, exits at 12×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 10.0% | 17.81 |
| FY28 | 10.0% | 19.59 |
| FY29 | 10.0% | 21.55 |
| FY30 | 10.0% | 23.70 |
| FY31 | 10.0% | 26.07 |
| FY32 | 8.0% ·fade | 28.16 |
| FY33 | 6.0% ·fade | 29.85 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.